US stock futures dip as Trump’s firing of Cook sparks Fed independence fears
WARSAW, Ind. - OrthoPediatrics Corp. (NASDAQ:KIDS), a company dedicated to pediatric orthopedics, reported preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2024, and provided financial guidance for 2025. The company, currently valued at approximately $603 million, announced a significant year-over-year revenue increase and anticipates continued growth and profitability. According to InvestingPro data, the company maintains a strong financial health profile with an impressive current ratio of 7.17, indicating robust liquidity.
In 2024, OrthoPediatrics achieved a record net revenue of approximately $204.7 million, a 38% increase from $148.7 million in 2023. This growth is attributed to both domestic and international sales, with domestic revenue rising by 45% to $161.1 million and international revenue by 16% to $43.6 million. The fourth quarter alone saw a 40% revenue increase to $52.7 million compared to the same period in the previous year. The company maintains an impressive gross profit margin of 73.68%, demonstrating strong operational efficiency. Based on InvestingPro's Fair Value analysis, the stock appears slightly overvalued at current levels.
The company's President and CEO, David Bailey, highlighted the success of their Trauma and Deformity, Scoliosis, and specialty bracing businesses, noting the opportunities for further expansion and impact on pediatric care.
Looking ahead, OrthoPediatrics projects its 2025 revenue to be in the range of $235 million to $242 million, indicating a 15% to 18% growth. Additionally, the company expects to generate between $15 million to $17 million of adjusted EBITDA for the full year. InvestingPro reveals that two analysts have recently revised their earnings estimates upward for the upcoming period, suggesting growing confidence in the company's outlook. For deeper insights into KIDS and 1,400+ other stocks, subscribers can access comprehensive Pro Research Reports that transform complex financial data into actionable intelligence.
The provided financial figures are preliminary and subject to the completion of review and audit procedures. OrthoPediatrics plans to release its finalized fourth quarter and full year 2024 financial results in early March.
This announcement contains forward-looking statements that are subject to various risks and uncertainties, including those related to public health emergencies and other factors detailed in OrthoPediatrics' SEC filings.
The financial measures such as adjusted EBITDA mentioned are non-GAAP, and reconciliations to GAAP measures will be provided with the upcoming earnings release.
OrthoPediatrics, established in 2006, is committed to the pediatric orthopedic market, offering over 70 products across trauma and deformity, scoliosis, and sports medicine. The company operates in the United States and over 70 countries globally.
This article is based on a press release statement from OrthoPediatrics Corp.
In other recent news, OrthoPediatrics Corporation reported a significant 37% increase in Q3 revenue, reaching a record $54.6 million. This growth was attributed to new product launches, gains in market share, and strong performance in key segments such as trauma, deformity, and scoliosis. The company also served over 33,000 children, marking a 50% increase from the previous year. Meanwhile, Procept BioRobotics reported robust revenue growth of 66% in the third quarter, totaling approximately $58.4 million.
In analyst notes, Morgan Stanley (NYSE:MS) initiated coverage on Procept BioRobotics with an Overweight rating, while Jefferies and BTIG maintain a Hold and Neutral rating respectively. Truist Securities maintained a Buy rating on Procept BioRobotics, raising its price target to $105 following the company's strong third-quarter performance. On the other hand, Piper Sandler expressed optimism for several healthcare companies, including ATEC, ATRC, and KIDS, anticipating positive fiscal year outlooks.
OrthoPediatrics also expanded its brace technology with new products, and Boston Orthotics & Prosthetics, a subsidiary of OrthoPediatrics, introduced a Bluetooth-enabled sensor system for scoliosis braces. This recent development is part of the company's ongoing efforts to enhance its product line and reinforce its position in the pediatric orthopedic industry. Similarly, Procept BioRobotics initiated a public offering of common stock valued at $175 million, showcasing its financial performance and growth strategy. These are recent developments in the companies' growth and potential in their respective market sectors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.